EVENTS · DXCM
PEERS
EARNINGS
DexCom Inc. is a medical device company focused on continuous glucose monitoring systems for diabetes and metabolic health. Dexcom develops wearable biosensors, transmitters, receivers, and software that provide real-time glucose readings, trend data, and alerts to help users and clinicians monitor glucose levels without routine fingerstick testing. Its current product lineup includes Dexcom G7, Dexcom G7 15 Day, Dexcom G6, Dexcom ONE+, Stelo, Dexcom Share, and Dexcom Follow, along with digital tools and remote monitoring features that support daily diabetes management. The company serves people with diabetes, adults with prediabetes and type 2 diabetes who do not use insulin, and healthcare professionals across the United States and international markets. Headquartered in San Diego, California, DexCom plays a significant role in the diabetes care technology market through its focus on connected glucose sensing and data-sharing solutions.
No company news, with medical device makers higher as a group while the broader market also gained
The board authorized a share repurchase program.
| Series | 1W | 1M |
|---|---|---|
| DXCM | +12.5% | +6.1% |
| Peers | +5.9% | +12.6% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 91 | 40 |
| QUARTER | EPS EST | EPS ACTUAL | EPS SURPRISE | REACTION |
|---|---|---|---|---|
| Q3 FY2026 | 0.66 | — | — | +4.67% |
| Q2 FY2026 | 0.62 | 0.70 | +12.38% | +11.06% |
| Q1 FY2026 | 0.48 | 0.56 | +17.03% | +6.58% |
| Q4 FY2025 | 0.66 | 0.45 | −32.13% | +2.74% |
| Q3 FY2025 | 0.58 | 0.61 | +5.32% | −14.61% |
| Series | 1W | 1M |
|---|---|---|
| DXCM | +12.5% | +6.1% |
| Peers | +5.9% | +12.6% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 91 | 40 |
